DK1425035T3 - Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling.. - Google Patents

Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling..

Info

Publication number: DK1425035T3
Authority: DK; Denmark
Prior art keywords: preventative; tat; targeting; fragments; derivatives
Prior art date: 2001-07-26

Application number

DK02767265.8T

Other languages

English (en)

Inventor

Barbara Ensoli

Original Assignee

Ist Superiore Sanita

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-26

Filing date

2002-07-26

Publication date

2011-08-29

2002-07-26 Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita

2011-08-29 Application granted granted Critical

2011-08-29 Publication of DK1425035T3 publication Critical patent/DK1425035T3/da

Links

241000713772 Human immunodeficiency virus 1 Species 0.000 title 1
230000003213 activating effect Effects 0.000 title 1
210000000612 antigen-presenting cell Anatomy 0.000 title 1
239000012634 fragment Substances 0.000 title 1
230000008685 targeting Effects 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
238000002255 vaccination Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Mycology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Hematology (AREA)

DK02767265.8T 2001-07-26 2002-07-26 Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling.. DK1425035T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01118114A EP1279404A1 (en)	2001-07-26	2001-07-26	Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
PCT/EP2002/008377 WO2003009867A1 (en)	2001-07-26	2002-07-26	Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases

Publications (1)

Publication Number	Publication Date
DK1425035T3 true DK1425035T3 (da)	2011-08-29

Family

ID=8178141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02767265.8T DK1425035T3 (da)	2001-07-26	2002-07-26	Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling..

Country Status (19)

Country	Link
US (1)	US7811573B2 (da)
EP (2)	EP1279404A1 (da)
JP (1)	JP5134183B2 (da)
CN (1)	CN1318091C (da)
AP (1)	AP2004002986A0 (da)
AT (1)	ATE510558T1 (da)
AU (1)	AU2002331350B2 (da)
BR (1)	BR0211474A (da)
CA (1)	CA2455227C (da)
DK (1)	DK1425035T3 (da)
EA (1)	EA006850B1 (da)
ES (1)	ES2367255T3 (da)
HU (1)	HUP0400660A2 (da)
IL (1)	IL160015A0 (da)
MX (1)	MXPA04000287A (da)
NZ (1)	NZ531364A (da)
OA (1)	OA12701A (da)
PL (1)	PL368243A1 (da)
WO (1)	WO2003009867A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0323840D0 (en) *	2003-10-10	2003-11-12	Ist Superiore Sanita	Vaccines
GB0405480D0 (en)	2004-03-11	2004-04-21	Istituto Superiore Di Sanito	Novel tat complexes,and vaccines comprising them
US20050208482A1 (en)	2004-03-16	2005-09-22	Cohen David I	Tat-based immunomodulatory compositions and methods for their discovery and use
WO2007001448A2 (en)	2004-11-04	2007-01-04	Massachusetts Institute Of Technology	Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CN100429228C (zh) *	2005-06-17	2008-10-29	中国人民解放军第三军医大学第三附属医院	重组人a20蛋白及其用途
US9267937B2 (en)	2005-12-15	2016-02-23	Massachusetts Institute Of Technology	System for screening particles
WO2008105773A2 (en)	2006-03-31	2008-09-04	Massachusetts Institute Of Technology	System for targeted delivery of therapeutic agents
US8367113B2 (en)	2006-05-15	2013-02-05	Massachusetts Institute Of Technology	Polymers for functional particles
WO2007150030A2 (en)	2006-06-23	2007-12-27	Massachusetts Institute Of Technology	Microfluidic synthesis of organic nanoparticles
CA2660830A1 (en)	2006-08-14	2008-02-21	Gideon Goldstein	Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
US9217129B2 (en)	2007-02-09	2015-12-22	Massachusetts Institute Of Technology	Oscillating cell culture bioreactor
US20090074828A1 (en)	2007-04-04	2009-03-19	Massachusetts Institute Of Technology	Poly(amino acid) targeting moieties
MX2010003642A (es)	2007-10-12	2010-08-09	Massachusetts Inst Technology	Nanotecnologia de vacuna.
GB0802224D0 (en) *	2008-02-06	2008-03-12	Inst Superiore Di Sanito	Process for the production of vaccine components
CN101980738A (zh)	2008-02-07	2011-02-23	华盛顿大学	圆周气雾设备
EP2106803A1 (en) *	2008-04-04	2009-10-07	Fondazione Centro San Raffaele del Monte Tabor	Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
WO2009139004A2 (en) *	2008-05-14	2009-11-19	Jawaharlal Nehru Centre For Advanced Scientific Research	Tat dna sequences, gene constructs, vaccine and processes thereof
US8277812B2 (en)	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8343497B2 (en)	2008-10-12	2013-01-01	The Brigham And Women's Hospital, Inc.	Targeting of antigen presenting cells with immunonanotherapeutics
JP5692933B2 (ja)	2009-03-23	2015-04-01	ナニアールエックスセラピューティックスインコーポレイテッド	免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
AU2011217955A1 (en) *	2010-02-18	2012-08-16	Emory University	Vectors expressing HIV antigens and GM-CSF and related methods for generating an immune response
US20110287045A1 (en) *	2010-05-20	2011-11-24	Zongdong Li	Enhanced immune response against infections
EP2680913B1 (en)	2011-03-03	2020-05-06	Impel NeuroPharma Inc.	Nasal drug delivery device
CN107376071B (zh)	2011-05-09	2021-07-09	英倍尔药业股份有限公司	用于将化合物递送到使用者的上部嗅觉区的喷嘴
AU2013316679B2 (en) *	2012-09-13	2017-12-14	Les Hopitaux Universitaires De Geneve	Cell penetrating peptides
CN103880961A (zh) *	2012-12-19	2014-06-25	邱书奇	一种诱导免疫耐受融合肽构建
HK1222358A1 (zh)	2013-04-28	2017-06-30	Impel Neuropharma Inc.	医用单位剂量容器
WO2015051245A1 (en)	2013-10-04	2015-04-09	Pin Pharma, Inc.	Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
ES2804750T3 (es) *	2014-04-24	2021-02-09	Janssen Sciences Ireland Unlimited Co	Uso de una proteína accesoria derivada del VIH para la reactivación del VIH latente
EP3341059B1 (en)	2015-09-10	2022-03-02	Impel NeuroPharma Inc.	In-line nasal delivery device
CN109071592B (zh)	2016-01-08	2022-07-19	吉奥瓦科斯公司	用于产生对肿瘤相关抗原的免疫应答的组合物和方法
CN105535937B (zh) *	2016-03-11	2018-03-13	刘红	一种用于治疗类风湿性关节炎的皮下注射用原位凝胶
CN110225760B (zh) *	2016-09-15	2023-11-07	埃里西拉医疗公司	T细胞免疫疗法
US11311612B2 (en)	2017-09-19	2022-04-26	Geovax, Inc.	Compositions and methods for generating an immune response to treat or prevent malaria
KR102131898B1 (ko) *	2017-10-31	2020-07-08	주식회사 노벨티노빌리티	Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
US11395887B2 (en)	2017-11-21	2022-07-26	Impel Pharmaceuticals Inc.	Intranasal device with inlet interface
US11571532B2 (en)	2017-11-21	2023-02-07	Impel Pharmaceuticals Inc.	Intranasal device with dip tube
BR112020013744A8 (pt)	2018-01-05	2022-10-18	Impel Neuropharma Inc	Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
EP3735223A4 (en)	2018-01-05	2021-10-13	Impel Neuropharma Inc.	INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
JP2021532098A (ja)	2018-07-19	2021-11-25	インペルニューロファーマインコーポレイテッド	パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
CN113473967B (zh)	2019-01-03	2022-09-09	英倍尔制药公司	经鼻药物递送装置
CN113287013B (zh) *	2019-01-04	2025-04-15	国立大学法人京都大学	溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
AU2020277313A1 (en)	2019-05-17	2022-01-20	Impel Pharmaceuticals Inc.	Single-use nasal delivery device
CN113939313B (zh) *	2019-06-06	2024-11-01	电化株式会社	以肽核酸为基础的佐剂
WO2021135647A1 (zh) *	2019-12-31	2021-07-08	厦门大学	用于胞内递送分子的多聚化递送系统
CN111450082A (zh) *	2020-04-26	2020-07-28	天津大学	一种系统性红斑狼疮治疗纳米颗粒的合成方法
CN115869416A (zh) *	2021-09-28	2023-03-31	上海交通大学医学院附属第九人民医院	用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9720585D0 (en) *	1997-09-26	1997-11-26	Smithkline Beecham Biolog	Vaccine
IT1297090B1 (it) *	1997-12-01	1999-08-03	Barbara Ensoli	Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FI105105B (fi) *	1998-02-27	2000-06-15	Finnish Immunotechnology Ltd O	Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
AU4082300A (en) *	1999-06-21	2001-01-09	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Hiv tat peptides and multiple peptide conjugate system
ES2250151T3 (es)	1999-06-29	2006-04-16	Glaxosmithkline Biologicals S.A.	Uso de cpg como adyuvante de vacuna contra vih.
AU785258B2 (en)	1999-08-12	2006-12-07	Nanirx, Inc.	Non-immunosuppressant HIV tat
WO2001019393A1 (en) *	1999-09-13	2001-03-22	Cornell Research Foundation, Inc.	Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems
AU2001234616A1 (en)	2000-01-31	2001-08-07	Vic Jira	Vaccine composition, process and methods
JP2003529559A (ja)	2000-01-31	2003-10-07	グラクソスミスクラインバイオロジカルズソシエテアノニム	新規用途
US6544780B1 (en)	2000-06-02	2003-04-08	Genphar, Inc.	Adenovirus vector with multiple expression cassettes
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung

2001
- 2001-07-26 EP EP01118114A patent/EP1279404A1/en not_active Withdrawn
2002
- 2002-07-26 PL PL02368243A patent/PL368243A1/xx unknown
- 2002-07-26 AU AU2002331350A patent/AU2002331350B2/en not_active Ceased
- 2002-07-26 IL IL16001502A patent/IL160015A0/xx not_active IP Right Cessation
- 2002-07-26 AP APAP/P/2004/002986A patent/AP2004002986A0/en unknown
- 2002-07-26 US US10/485,180 patent/US7811573B2/en not_active Expired - Fee Related
- 2002-07-26 OA OA1200400015A patent/OA12701A/en unknown
- 2002-07-26 AT AT02767265T patent/ATE510558T1/de not_active IP Right Cessation
- 2002-07-26 HU HU0400660A patent/HUP0400660A2/hu unknown
- 2002-07-26 CA CA2455227A patent/CA2455227C/en not_active Expired - Fee Related
- 2002-07-26 ES ES02767265T patent/ES2367255T3/es not_active Expired - Lifetime
- 2002-07-26 EA EA200400227A patent/EA006850B1/ru not_active IP Right Cessation
- 2002-07-26 NZ NZ531364A patent/NZ531364A/en not_active IP Right Cessation
- 2002-07-26 JP JP2003515259A patent/JP5134183B2/ja not_active Expired - Fee Related
- 2002-07-26 MX MXPA04000287A patent/MXPA04000287A/es not_active Application Discontinuation
- 2002-07-26 CN CNB028146581A patent/CN1318091C/zh not_active Expired - Fee Related
- 2002-07-26 BR BR0211474-7A patent/BR0211474A/pt not_active IP Right Cessation
- 2002-07-26 DK DK02767265.8T patent/DK1425035T3/da active
- 2002-07-26 WO PCT/EP2002/008377 patent/WO2003009867A1/en not_active Ceased
- 2002-07-26 EP EP02767265A patent/EP1425035B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1318091C (zh)	2007-05-30
CN1533284A (zh)	2004-09-29
EP1425035B1 (en)	2011-05-25
JP5134183B2 (ja)	2013-01-30
ATE510558T1 (de)	2011-06-15
IL160015A0 (en)	2004-06-20
ES2367255T3 (es)	2011-10-31
CA2455227A1 (en)	2003-02-06
US7811573B2 (en)	2010-10-12
EP1279404A1 (en)	2003-01-29
AP2004002986A0 (en)	2004-03-31
EP1425035A1 (en)	2004-06-09
PL368243A1 (en)	2005-03-21
HUP0400660A2 (hu)	2005-01-28
JP2005505520A (ja)	2005-02-24
US20050036985A1 (en)	2005-02-17
CA2455227C (en)	2012-01-24
AU2002331350B2 (en)	2008-06-12
BR0211474A (pt)	2004-07-13
EA200400227A1 (ru)	2004-06-24
OA12701A (en)	2006-06-23
NZ531364A (en)	2005-12-23
WO2003009867A1 (en)	2003-02-06
EA006850B1 (ru)	2006-04-28
MXPA04000287A (es)	2005-03-07

Publication	Publication Date	Title
IL160015A0 (en)	2004-06-20	Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
NO20050497L (no)	2005-03-08	Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
MXPA05008406A (es)	2006-02-17	Compuestos de amida tri(ciclo)-sustituida.
EE200300212A (et)	2003-08-15	Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
NO20065195L (no)	2007-01-18	Terapeutiske enzymformuleringer og anvendelser derav
IS7431A (is)	2004-08-31	Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
FR16C0028I2 (fr)	2018-05-11	Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
DE60035778D1 (de)	2007-09-13	Rekombinante influenzaviren zur vakzinherstellung und gentherapie
EE05074B1 (et)	2008-10-15	Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
TR199903053T2 (xx)	2000-11-21	Benzimidazol t�revleri.
DK0853660T3 (da)	2003-05-05	Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
BRPI0413427A (pt)	2006-10-10	derivados de piridilpirrol ativos como inibidores da cinase
NO20024238D0 (no)	2002-09-05	Peptidase-spaltbare, målsökende antineoplastiske medikamenter, og deres terapautiske anvendelse
DE60332355D1 (de)	2010-06-10	Hla-a24-restringiertes krebsantigenpeptid
MY152540A (en)	2014-10-15	Powder formulation for valganciclovir
JO2178B1 (en)	2003-04-23	Treatment of emphysema using rar selective retinoid antagonists
DE112004000961D2 (de)	2006-02-23	Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
NO20055838L (no)	2006-02-13	Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
ATE504313T1 (de)	2011-04-15	Vakzine, welche gp120 zusammen mit nef und/oder tat enthält, zur immunisierung gegen hiv
NO331083B1 (no)	2011-10-03	Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati
WO2006010106A3 (en)	2006-06-01	Dna-based vaccination of retroviral-infected individuals undergoing treatment
TW200716749A (en)	2007-05-01	Interferon-beta gene therapy using an improved, regulated expression system
AR053154A1 (es)	2007-04-25	Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina
HK1062536A (en)	2004-11-12	Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases